Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial-Reference-Cited by-同舟云学术

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

Published:2016-06-24 Issue:13 Volume:23 Page:4169-4177
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Andtbacka Robert H. I.,Ross Merrick,Puzanov Igor,Milhem Mohammed,Collichio Frances,Delman Keith A.,Amatruda Thomas,Zager Jonathan S.,Cranmer Lee,Hsueh Eddy,Chen Lisa,Shilkrut Mark,Kaufman Howard L.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-016-5286-0.pdf

Reference16 articles.

1. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy. 2003;10(4):292–303.

2. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–71.

3. Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;33(25):2780–88.

4. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737–47.

5. Hodi FS, Sznol M, Kluger HM, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. ASCO Meeting Abstracts. 2014 2014;32(15 Suppl):9002.

Cited by 247 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regional and intratumoral adoptive T-cell therapy;Immuno-Oncology and Technology;2024-12

2. A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors;Radiotherapy and Oncology;2024-11

3. Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?;European Journal of Cancer;2024-09

4. Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,;European Journal of Cancer;2024-08

5. Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions;Radiology;2024-07-01